Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity

Area of Science:

• Immunology
• Cancer Biology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for hematological cancers but struggles with solid tumor specificity.
• Natural T cells with T cell receptors (TCRs) offer better cancer cell discrimination but lack tumor-killing potency.

Purpose of the Study:

• To investigate the impact of co-expressing TCR and CAR on the same T cell.
• To engineer dual-engineered T cells for enhanced solid tumor immunotherapy.

Main Methods:

• Utilized a high-throughput platform to systematically assess TCR-CAR co-expression effects.
• Developed mathematical models to capture TCR-CAR crosstalk dynamics.
• Engineered dual TCR/CAR T cells targeting specific neoantigens and HER2 ligands.

Main Results:

• Strong TCR-antigen interactions boosted CAR activation; weak interactions caused antagonism.
• Engineered dual TCR/CAR T cells demonstrated enhanced anti-cancer activity in a solid tumor model.
• Dual-engineered T cells exhibited reduced toxicity toward healthy tissues compared to conventional CAR T cells.

Conclusions:

• TCR-CAR crosstalk can be harnessed to improve T cell therapy specificity and efficacy.
• Dual-engineered T cells represent a promising strategy for overcoming solid tumor treatment challenges.
• This approach paves the way for more precise and effective cancer immunotherapies.